GW Pharmaceuticals recognised for leadership in prescription cannabis-based medicines with prestigious Queen’s Award for Enterprise in Innovation
28 avr. 2021 20h00 HE
|
GW Pharmaceuticals plc
LONDON, April 29, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and commercialising regulatory...
GW Pharmaceuticals Shareholders Approve Acquisition by Jazz Pharmaceuticals
23 avr. 2021 16h01 HE
|
GW Pharmaceuticals plc
LONDON and DUBLIN, April 23, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH) (GW) and Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (Jazz) today announced that GW’s shareholders voted to...
GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures associated with tuberous sclerosis complex
20 avr. 2021 06h30 HE
|
GW Pharmaceuticals plc
– Tuberous sclerosis complex (TSC) represents a third indication for GW’s cannabidiol in Europe – – TSC causes epilepsy in up to 85% of patients, and up to 60% of those patients do not respond to...
GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences to Present Data at the 2021 American Academy of Neurology (AAN) Annual Meeting
13 avr. 2021 08h30 HE
|
GW Pharmaceuticals plc
EPIDOLEX encore presentations highlight long-term safety and efficacy data in patients with tuberous sclerosis complex (TSC) and other treatment-resistant epilepsies Nabiximols data show efficacy and...
GW Pharmaceuticals receives positive CHMP opinion for EPIDYOLEX® (cannabidiol) for use as treatment of seizures associated with Tuberous Sclerosis Complex
26 févr. 2021 07h15 HE
|
GW Pharmaceuticals plc
LONDON, Feb. 26, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and delivering regulatory approved...
GW Pharmaceuticals plc Reports Fourth Quarter and Year-End 2020 Financial Results and Operational Progress
16 févr. 2021 07h00 HE
|
GW Pharmaceuticals plc
– Total revenue of $148.2 million for the fourth quarter and $527.2 million for the full year – – Total Epidiolex® net product sales of $144.1 million for the fourth quarter and $510.5 million for...
GW Pharmaceuticals Provides Preliminary Fourth Quarter and Full-Year 2020 Net Product Sales Results and 2021 Program Milestones
11 janv. 2021 07h00 HE
|
GW Pharmaceuticals plc
- Total preliminary net product sales of approximately $148 million for the fourth quarter and approximately $526 million for the full year -- Total Epidiolex® preliminary net product sales of...
CORRECTING and REPLACING - GW Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference
05 janv. 2021 12h24 HE
|
GW Pharmaceuticals plc
LONDON and CARLSBAD, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- In a release issued earlier today by GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group) under the same headline,...
GW Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference
05 janv. 2021 07h30 HE
|
GW Pharmaceuticals plc
LONDON and CARLSBAD, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and...
JAMA Neurology Publishes Phase 3 Study of EPIDIOLEX® (cannabidiol) Oral Solution in Patients with Seizures Associated with Tuberous Sclerosis Complex
21 déc. 2020 11h30 HE
|
GW Pharmaceuticals plc
CARLSBAD, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of...